OXFORD BIOMEDICA AND ITS COLLABORATORS TO REPORT TROVAX® CLINICAL TRIAL RESULTS AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
Oxford
BioMedica (LSE: OXB), the leading gene therapy company,
and Cancer Research UK are scheduled to deliver two poster
presentations, describing results from Phase II trials
of TroVax in colorectal cancer, at the American Society
of Clinical Oncology (ASCO) Annual Meeting, to be held
on 2-6 June in Atlanta, Georgia, USA. The Company’s
US clinical collaborators have had a further two abstracts,
covering preliminary results from clinical trials of TroVax
in renal cell carcinoma, selected for publication in the
ASCO Proceedings.
The two colorectal cancer poster presentations and the two
renal cell carcinoma abstracts include new data from five
clinical trials of TroVax. The titles of the presentations/abstracts
are set out below:
“Open label Phase II studies of Modified Vaccinia
Ankara expressing the tumour antigen 5T4 given in conjunction
with IFL and FOLFOX chemotherapy regimens: final analysis
of safety and immunogenicity of MVA 5T4 given before, during
and after chemotherapy”, to be presented by Dr Richard
Harrop, Director Clinical Immunology at Oxford BioMedica.
“A vaccinia-based vaccine (TroVax) targeting the
oncofetal antigen 5T4 administered before and after surgical
resection of colorectal cancer liver metastases: Phase
II trial”, to be presented by Dr Adam Dangoor of
the Christie Hospital, Manchester, UK. This investigator-initiated
trial is sponsored by Cancer Research UK.
“A Phase I clinical trial of MVA vaccine expressing
5T4 and high-dose interleukin-2 for metastatic renal cell
carcinoma”. The principal investigator for this
trial and lead author of the abstract is Dr Howard Kaufmann
of the New York-Presbyterian Hospital, New York, USA.
“A Phase II trial to assess the activity of MVA-5T4
plus interleukin-2 in patients with metastatic renal cell
carcinoma”. The principal investigator for this
trial and lead author of the abstract is Dr. Robert Amato
of the Methodist Hospital, Houston, Texas, USA.
Oxford BioMedica's CEO, Professor Alan Kingsman, said: "We
are delighted that the Scientific Program Committee of ASCO has
accepted all of the abstracts that were submitted for TroVax, and
that two abstracts have been selected for presentation. The exposure
of TroVax at this prestigious clinical oncology meeting increases
year by year, which reflects the expansion of the clinical programme
and the encouraging results from these trials. "
-
ends - |
